Molecular glues and PROTACs: Past, Present, and Future

Targeted protein degradation has emerged as a powerful modality in cancer therapeutics. Small molecules can selectively eliminate disease-associated proteins by co-opting the cell’s ubiquitin-proteasome system. This includes proteins previously deemed undruggable. This collection focuses on the progress, current clinical landscape, and future directions of these technologies. It explores both molecular glues and proteolysis targeting chimeras, known as PROTACs.This Research Topic seeks to compile research on the design, synthesis, and evaluation of new degrader molecules. I’m keen to receive contributions that address key hurdles in the field. These include discovering alternative E3 ligase ligands, improving tissue-specific targeting, and understanding mechanisms of resistance to degraders.I welcome submissions of Original Research, Reviews, Mini Reviews, Perspectives, and Brief Research Reports. Relevant themes include:Design and synthesis of new molecular glues and PROTACsIdentification and characterization of alternative E3 ligasesStructural biology and biophysical characterization of ternary complexesPharmacokinetics, pharmacodynamics, and translational oncology of degradersStrategies to overcome resistance mechanisms in cancer treatment Topic editors: SREEKANTH THOTA Source: https://www.frontiersin.org/research-topics/83072/molecular-glues-and-protacs-past-present-and-future